LTA4H抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal brain tissue, Primary antibody: P08487(LTA4H Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08487(LTA4H Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of LTA4H Antibodies**

Leukotriene A4 hydrolase (LTA4H) is a bifunctional zinc metalloenzyme involved in inflammatory processes. It catalyzes the hydrolysis of leukotriene A4 (LTA4) to pro-inflammatory leukotriene B4 (LTB4), a potent chemoattractant linked to neutrophil recruitment, and also exhibits aminopeptidase activity. LTA4H is part of the M1 family of aminopeptidases and is expressed in various immune cells, including neutrophils, macrophages, and epithelial cells. Its dual enzymatic roles position it as a key regulator in both promoting and resolving inflammation, depending on substrate availability and cellular context.

Dysregulation of LTA4H is implicated in chronic inflammatory diseases (e.g., COPD, rheumatoid arthritis), atherosclerosis, and cancer progression. Elevated LTB4 levels are associated with tissue damage and disease severity, making LTA4H a therapeutic target. Antibodies targeting LTA4H are primarily used in research to study its expression, localization, and function. Some therapeutic antibodies or inhibitors aim to block LTA4H’s hydrolase activity to reduce LTB4-driven inflammation. However, challenges remain due to its dual enzymatic nature and potential off-target effects. Recent studies also explore its role in cancer metastasis and angiogenesis, broadening its therapeutic relevance. Current efforts focus on developing selective inhibitors or neutralizing antibodies, with several candidates in preclinical or early clinical trials.